S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
Log in

NYSE:HQLTekla Life Sciences Investors Stock Price, Forecast & News

$15.18
+0.07 (+0.46 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.12
Now: $15.18
$15.60
50-Day Range
$12.22
MA: $15.26
$17.99
52-Week Range
$11.45
Now: $15.18
$18.00
Volume142,500 shs
Average Volume130,413 shs
Market Capitalization$345.44 million
P/E RatioN/A
Dividend Yield9.66%
Beta1.24
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Investment offices, not elsewhere classified
Sub-IndustryN/A
SectorFinance
CUSIPN/A
Phone617-772-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$345.44 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HQL News and Ratings via Email

Sign-up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.


Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions

How has Tekla Life Sciences Investors' stock been impacted by COVID-19 (Coronavirus)?

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HQL stock has increased by 2.2% and is now trading at $15.18. View which stocks have been mosted impacted by Coronavirus.

How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?

Tekla Life Sciences Investors announced a quarterly dividend on Wednesday, February 19th. Stockholders of record on Friday, February 28th will be given a dividend of $0.39 per share on Tuesday, March 31st. This represents a $1.56 dividend on an annualized basis and a yield of 10.28%. The ex-dividend date of this dividend is Thursday, February 27th. This is a boost from Tekla Life Sciences Investors's previous quarterly dividend of $0.37. View Tekla Life Sciences Investors' dividend history.

Has Tekla Life Sciences Investors been receiving favorable news coverage?

Headlines about HQL stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tekla Life Sciences Investors earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutTekla Life Sciences Investors.

Are investors shorting Tekla Life Sciences Investors?

Tekla Life Sciences Investors saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 4,100 shares, a decrease of 87.3% from the February 27th total of 32,400 shares. Based on an average daily trading volume, of 104,800 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company's shares are sold short. View Tekla Life Sciences Investors' Current Options Chain.

Who are some of Tekla Life Sciences Investors' key competitors?

What other stocks do shareholders of Tekla Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include Enbridge (ENB), Tekla Healthcare Investors (HQH), Gilead Sciences (GILD), AbbVie (ABBV), Apple Hospitality REIT (APLE), Enterprise Products Partners (EPD), Energy Transfer LP Unit (ET), IBM (IBM), Altria Group (MO) and Walgreens Boots Alliance (WBA).

Who are Tekla Life Sciences Investors' key executives?

Tekla Life Sciences Investors' management team includes the following people:
  • Dr. Daniel R. Omstead M.S, Ph.D., Principal Exec. Officer, Pres and Trustee (Age 66)
  • Ms. Laura F. Woodward, Principal Financial Officer, Chief Compliance Officer, Sec. and Treasurer (Age 51)
  • Ms. Betty T. Chang, Assistant Treasurer (Age 47)

What is Tekla Life Sciences Investors' stock symbol?

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

How do I buy shares of Tekla Life Sciences Investors?

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tekla Life Sciences Investors' stock price today?

One share of HQL stock can currently be purchased for approximately $15.18.

How big of a company is Tekla Life Sciences Investors?

Tekla Life Sciences Investors has a market capitalization of $345.44 million.  View additional information about Tekla Life Sciences Investors.

What is Tekla Life Sciences Investors' official website?

The official website for Tekla Life Sciences Investors is http://www.teklacap.com/.

How can I contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel